We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

A. Menarini Diagnostics S.r.l.

A. Menarini Diagnostics S.r.l. is fully committed to developing high tech diagnostics instruments and reagents to imp... read more Featured Products: More products

Download Mobile App




Innovative All-in-One MDx Platform Addresses Needs of Medium-to-High Throughput Laboratories

By LabMedica International staff writers
Posted on 23 May 2023
Print article
Image: PRIME MDx all-in-one, sample-to-result, fully automated solution (Photo courtesy of Menarini)
Image: PRIME MDx all-in-one, sample-to-result, fully automated solution (Photo courtesy of Menarini)

The COVID-19 pandemic has brought significant changes to the molecular diagnostics market, driving it towards automation, user-friendliness, quick results, and reliability of tests. Despite remarkable progress in this field, many testing applications still depend on lab-developed tests and labor-intensive methods, which complicate the execution of large-scale automated diagnostics solutions. To address these challenges and market trends, a new all-in-one, fully automated molecular diagnostics platform is now available for the processing of various testing portfolios through real-time PCR.

Menarini Diagnostics (Florence, Italy) has launched its PRIME MDx system which allows users to handle various sample types by cleverly utilizing pre-filled plates along with a universal extraction solution. It can run up to five different assays per sample, reaching a maximum capacity of 240 samples per day. The system's continuous workflow feature allows users to initiate a new loading process (extraction/setup) even while a previous PCR is still running. Its AI-driven software guarantees a smooth user experience, from uninterrupted sample loading to result interpretation, resulting in high-quality results, standardized workflows, and enhanced lab efficiency. PRIME MDx's automation and guided instrument setup minimize manual intervention and guarantee full sample traceability.

PRIME MDx offers the flexibility to manage runs with various extraction reagent formats (prefilled or standard) and seamlessly integrates with the existing IT infrastructure. This fully automated sample-to-result system is specifically engineered to simplify laboratory workflows for real-time PCR diagnostic assays, delivering outstanding efficiency, flexibility, and user-friendliness. The system is being introduced with two test panels, one for viral upper respiratory tract infections and another for viral transplant infections, applicable to a broad spectrum of sample matrices. Additional test panels are currently in the development phase to broaden the offerings.

"We are proud to bring this innovative, all-in-one, molecular diagnostics solution to the market, which will allow us to address the needs of medium-to-high throughput laboratories internationally and strengthen the position of A. Menarini Diagnostics in the molecular space," said Fabio Piazzalunga, General Manager and Global Head of Diagnostics Division in Menarini Group.

Related Links:
Menarini Diagnostics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.